Aims & Scope
Journal of Advanced Therapeutic Science (JATS) publishes original research, systematic reviews, and methodological innovations that advance the translation of therapeutic discoveries from bench to bedside across pharmaceutical sciences, clinical therapeutics, and precision medicine.
Core Research Domains
Drug Discovery & Development
- Medicinal chemistry and rational drug design
- Pharmacokinetics and pharmacodynamics (PK/PD modeling)
- Drug formulation and delivery systems
- Preclinical to clinical translation pathways
- Bioequivalence and biosimilar development
- Regulatory science and drug approval strategies
"Structure-based design of novel EGFR inhibitors with improved blood-brain barrier penetration: PK/PD modeling and Phase I clinical validation in glioblastoma patients"
Clinical Therapeutics & Precision Medicine
- Personalized treatment strategies based on genetic/molecular profiling
- Pharmacogenomics and biomarker-guided therapy
- Clinical trial design and adaptive trial methodologies
- Comparative effectiveness research
- Therapeutic drug monitoring and dose optimization
- Real-world evidence and post-market surveillance
"Pharmacogenomic-guided warfarin dosing reduces adverse events: Results from a multicenter randomized controlled trial with 18-month follow-up"
Immunotherapeutics & Biologics
- Cancer immunotherapy (checkpoint inhibitors, CAR-T, vaccines)
- Monoclonal antibodies and antibody-drug conjugates
- Cell-based therapeutics and regenerative medicine
- Vaccine development and immunization strategies
- Autoimmune disease therapeutics
- Biologic manufacturing and quality control
"Next-generation CAR-T cells with enhanced tumor infiltration and reduced cytokine release syndrome: Preclinical validation and first-in-human Phase I/II trial design"
Rare Disease & Orphan Drug Therapeutics
- Orphan drug development and regulatory pathways
- Gene therapy for inherited metabolic diseases
- Enzyme replacement therapy for lysosomal storage disorders
- Rare disease natural history studies with therapeutic endpoints
- Small molecule therapeutics for rare genetic conditions
- Patient-centered outcome measures in rare diseases
"AAV-mediated gene therapy for Fabry disease: Long-term efficacy and safety data from a 5-year open-label extension study with biomarker correlates"
Secondary Focus Areas
Nanomedicine & Drug Delivery
Nanoparticle-based drug delivery systems, targeted therapeutics, controlled release formulations, and theranostic applications with demonstrated clinical potential.
Infectious Disease Therapeutics
Antimicrobial drug development, antiviral therapeutics, vaccine platforms, resistance mechanisms, and novel treatment strategies for emerging infectious diseases.
Neuropharmacology & CNS Therapeutics
CNS drug delivery challenges, neurodegenerative disease therapeutics, psychiatric medication development, and blood-brain barrier penetration strategies.
Cardiovascular & Metabolic Therapeutics
Novel cardiovascular drugs, metabolic syndrome interventions, diabetes therapeutics, lipid-lowering agents, and cardiometabolic disease management strategies.
Ethnopharmacology & Natural Products
Phytomedicine with validated bioactivity, natural product drug discovery, traditional medicine modernization, and botanical therapeutic standardization.
Regulatory Science & Health Policy
Drug approval pathways, regulatory framework analysis, health technology assessment, pharmacoeconomics, and access to medicines research.
Emerging Research Frontiers
AI-Driven Drug Discovery
Machine learning for target identification, AI-guided molecular design, predictive toxicology models, and computational drug repurposing with experimental validation.
CRISPR & Gene Editing Therapeutics
Gene editing platforms for therapeutic applications, in vivo genome editing, base editing and prime editing technologies, and clinical translation of gene editing therapies.
Microbiome-Targeted Therapeutics
Probiotic therapeutics, microbiome modulation strategies, fecal microbiota transplantation, and gut-organ axis therapeutic interventions with clinical endpoints.
RNA Therapeutics
mRNA vaccines and therapeutics, siRNA and antisense oligonucleotide drugs, RNA delivery technologies, and splice-modulating therapies for genetic diseases.
Article Types & Editorial Priorities
Fast-Track Review (14-21 days to first decision)
- Original Research Articles (full-length, 4,000-8,000 words)
- Systematic Reviews & Meta-Analyses (PRISMA-compliant)
- Clinical Trial Reports (Phase I-IV, prospective registration required)
- Methods & Protocols (validated, reproducible therapeutic methodologies)
Standard Review (28-35 days to first decision)
- Short Communications (rapid reports, 2,000-3,000 words)
- Data Notes (negative results, replication studies, datasets)
- Perspectives & Commentaries (invited or unsolicited, 1,500-2,500 words)
- Technical Notes (novel techniques with therapeutic applications)
Requires exceptional novelty or impact
- Opinion Pieces (must be data-informed, not purely speculative)
- Narrative Reviews (only if addressing critical knowledge gaps)
- Editorials (typically invited by Editor-in-Chief)
Editorial Standards & Requirements
Reporting Guidelines
Clinical Trials: CONSORT
Observational Studies: STROBE
Systematic Reviews: PRISMA
Animal Studies: ARRIVE 2.0
Diagnostic Studies: STARD
Data Transparency
Raw data deposition in public repositories required for all experimental studies. Clinical trial data sharing per ICMJE guidelines. Code availability for computational analyses.
Ethics & Compliance
IRB/Ethics committee approval required for human studies. IACUC approval for animal research. Clinical trial registration (ClinicalTrials.gov or equivalent) before enrollment.
Preprint Policy
Preprints on bioRxiv, medRxiv, or arXiv accepted. Must be disclosed at submission. Final published version will be linked to preprint. Does not constitute prior publication.
Conflict of Interest
Full disclosure of financial relationships, industry funding, patent applications, and consulting arrangements required. ICMJE conflict of interest form mandatory.
Authorship Criteria
ICMJE authorship criteria strictly enforced. CRediT taxonomy encouraged. Corresponding author responsible for all co-author approvals and disclosures.
Publication Metrics & Performance
(Priority 1 Articles)
(2023-2024)
(Post-Acceptance)
(CC BY 4.0)
Ready to Submit Your Research?
If your work advances therapeutic science through rigorous research, clinical translation, or methodological innovation, we invite you to submit to Journal of Advanced Therapeutic Science.
Still unsure if your manuscript fits our scope? Contact our editorial office at [email protected] with your title and abstract for a pre-submission inquiry (response within 3-5 business days).
Submit Your Manuscript
